The FDA announced on Oct. 10, 2025, that QuVa Pharma, Inc. voluntarily recalled R.E.C.K. compounded drug syringes due to the presence of particulate matter. Owners should contact the company for a full refund.
How to tell if you have it
- Brand: QuVa Pharma
- Product: R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution
- NDC: 70092-1433-50
- Lot codes: 10149179 through 10152861 (see full list in record)
- Volume: 50 mL syringe
- Distribution: U.S. Nationwide
The hazard
The recall is due to the presence of particulate matter in the syringes. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show QuVa Pharma, Inc. has 9 other recalls on record since March 30, 2016. Other recent recalls of similar products include GE Healthcare Omnipaque 300 mg/mL Injection Recall: Particulate Matter Hazard (March 24, 2026) and Cipla Lanreotide Injection Recall: Particulate Matter Hazard (Jan. 2, 2026).